C&L: ImaRx CEO resigns

Dr. Evan Unger has resigned as president and CEO of ImaRx so that he will have more time to devote to the scientific development of the company. Brad Zakes and Greg Cobb will staff the Office of the CEO on an interim basis. Dr. Unger will remain a member of the ImaRx board of directors and will head the company's scientific advisory board.

Scripps Health has created a new Translational Science Institute and Genomic Medicine program to be led by cardiologist and physician-scientist Eric J. Topol, M.D.

Catherine Burzik has resigned as president of Applied Biosystems.

Advancis Pharmaceutical has promoted Robert C. Low to vice president, finance and chief financial officer.

Athenagen has added two new managers: John Anthony Hey, Ph.D., vice president of non-clinical development and Carl F. Grove, vice president, development operations.

Acuity Pharmaceuticals has named Denis O'Shaughnessy, Ph.D., as senior vice president of clinical development.

Lpath announced that Genevieve Hansen, Ph.D., has been promoted to vice president of research.

Cyclacel Pharmaceuticals has appointed John Womelsdorf as vice president, business development.

Pam Morley, Ph.D., has joined Fluidigm Corporation as vice president, North American sales, service and support.

Gregory L. White has been appointed vice-president, operations of Ecopia. Dr Jim McAlpine, vice-president, chemistry and discovery, will assume direct responsibility of the discovery-related activities including the ECO-4601's analog program. Dr Emmanuel Zazopoulos, vice-president, operations, drug discoveries has left the company to take on new challenges.

MaryJane Rafii, Ph.D. has joined Bioenvision as vice president, regulatory affairs.

Insmed Incorporated has added Henry Bunsow as outside counsel to its legal team.

Stephen C. Glover has been appointed to Auriga Laboratories' board of directors.

Zymeworks has added Dr. Patrick McCroskey to its board of directors.

Dendrite International has named Clay Lifflander to the company's board of directors.

Suggested Articles

The money will support work on a biologic drug cocktail that Lumen thinks can be a scalable, inexpensive fix for gastrointestinal symptoms.

The readouts link the oral oxidative phosphorylation blocker imeglimin to near- and long-term improvements when given as a monotherapy and in combos.

Scientists at the University of Toronto, in collaboration with Agios, identified 182 genes that allow cancer cells to evade the immune system.